Page last updated: 2024-12-04
cycrimine
Description
Cycrimine is an anticholinergic drug that was originally developed for the treatment of Parkinson's disease. It acts by blocking the action of acetylcholine, a neurotransmitter that plays a role in muscle movement. Cycrimine is no longer commonly used for Parkinson's disease due to its significant side effects, including dry mouth, blurred vision, constipation, and urinary retention. However, it remains in use for the treatment of certain types of dystonia, a movement disorder characterized by involuntary muscle contractions.'
cycrimine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
cycrimine : A member of the class of piperidines that is 3-(piperidin-1-yl)propan-1-ol in which one of the hydrogen atoms at the 1-position is substituted by cyclopentyl, and the other is substituted by phenyl. A central anticholinergic, it is used as its hydrochloride salt in the management and treatment of Parkinson's disease. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 2911 |
| CHEMBL ID | 1201227 |
| CHEBI ID | 59692 |
| SCHEMBL ID | 249004 |
| MeSH ID | M0059182 |
Synonyms (36)
| Synonym |
|---|
| 1-piperidinepropanol, .alpha.-cyclopentyl-.alpha.-phenyl- |
| cycrimine |
| alpha-cyclopentyl-alpha-phenyl-1-piperidinepropanol |
| DB00942 |
| (+/-)-cycrimine |
| cycriminum |
| (+-)-cycrimine |
| 1-cyclopentyl-1-phenyl-3-(piperidin-1-yl)propan-1-ol |
| CHEBI:59692 , |
| 77-39-4 |
| cicrimina |
| L000920 |
| 1-cyclopentyl-1-phenyl-3-piperidin-1-ylpropan-1-ol |
| einecs 201-024-6 |
| unii-543567rfqq |
| 1-piperidinepropanol, alpha-cyclopentyl-alpha-phenyl- |
| 543567rfqq , |
| 1-phenyl-1-cyclopentyl-3-piperidino-1-propanol |
| cycriminum [inn-latin] |
| cycrimine [inn:ban] |
| cicrimina [inn-spanish] |
| CHEMBL1201227 |
| cycrimine [who-dd] |
| cycrimine [inn] |
| .alpha.-cyclopentyl-.alpha.-phenyl-1-piperidinepropanol |
| SCHEMBL249004 |
| SWRUZBWLEWHWRI-UHFFFAOYSA-N |
| 1-cyclopentyl-1-phenyl-3-(1-piperidinyl)-1-propanol # |
| HY-119918 |
| Q5199107 |
| DTXSID50861769 |
| NCGC00521081-01 |
| 1-piperidinepropanol, a-cyclopentyl-a-phenyl- |
| EN300-18563603 |
| CS-0078367 |
| 1-cyclopentyl-1-phenyl-3-piperidin-1-yl-propan-1-ol |
Roles (3)
| Role | Description |
|---|
| antiparkinson drug | A drug used in the treatment of Parkinson's disease. |
| muscarinic antagonist | A drug that binds to but does not activate muscarinic cholinergic receptors, thereby blocking the actions of endogenous acetylcholine or exogenous agonists. |
| antidyskinesia agent | Any compound which can be used to treat or alleviate the symptoms of dyskinesia. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (3)
| Class | Description |
|---|
| tertiary alcohol | A tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it. |
| piperidines | |
| tertiary amino compound | A compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (1)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 39.8107 | 0.0096 | 10.5250 | 35.4813 | AID1479145 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Ceullar Components (1)
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 6 (85.71) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 28.03
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 28.03 (24.57) | | Research Supply Index | 2.08 (2.92) | | Research Growth Index | 4.32 (4.65) | | Search Engine Demand Index | 31.58 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |